Analytical Data
-
Gene name
CDC34
- Application
-
Alternative Names
CDC34; E2-CDC34; UBC3; UBE2R1; Ubiquitin-Conjugating Enzyme E2 R1; Ubiquitin-protein ligase R1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P49427
-
Expression Region
Met1~Ser236
-
Molecular Weight
35kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDC34 is an essential gene involved in the regulation of the cell cycle, specifically in the context of ubiquitin-mediated protein degradation. It encodes an E2 ubiquitin-conjugating enzyme that plays a crucial role in the post-translational modification of proteins, facilitating their degradation via the proteasome. Research on CDC34 has been driven by its implications in various cellular processes, including apoptosis, DNA damage response, and signal transduction pathways. Aberrations in CDC34 expression or function have been linked to several diseases, particularly cancers, where dysregulated proteolysis can contribute to tumorigenesis. The study of CDC34 recombinant proteins allows researchers to investigate its enzymatic activity, substrate specificity, and interaction with E3 ligases, providing insights into the molecular mechanisms of cell cycle regulation and potential therapeutic targets. By employing recombinant techniques, scientists can elucidate the structural and functional characteristics of CDC34, paving the way for a better understanding of its role in maintaining cellular homeostasis and its impact on disease progression. This research is particularly relevant in the development of targeted therapies aimed at restoring normal cell cycle control in cancerous cells.
